RA Capital Reports New 5.8% Position In Recently Public Versartis Inc (VSAR)

Peter Kolchinsky’s RA Capital Management has initiated a new position in Versartis Inc (NASDAQ:VSAR). RA Capital owns 1.40 million shares of the company, a new filing with the Securities and Exchange Commission showed. The position is equates to 5.8% of common stock and is passive by nature.

Peter Kolchinsky

Recently, the company completed its initial public offering of 6.90 million common stock shares at a public offering price of $21 per share, which included 900,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares.  The company has a market cap of $676.1 million.

Versartis Inc (NASDAQ:VSAR) is an endocrine-focused biopharmaceutical company initially developing VRS-317, a novel, long-acting form of recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD). VRS-317 is intended to reduce the burden of daily treatment by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes. The company’s first targeted indication for VRS-317 is pediatric GHD, which represents an about $1.5 billion existing market opportunity.

Currently, the company is conducting the Phase 2a stage of its pediatric GHD clinical trial in which it is evaluating the dosing regimens of the drug. The company has global rights to VRS-317 and,  if it is approved, it intends to sell it via its own specialty sales force in the United States and Canada, as well as other regions.

Versartis Inc (NASDAQ:VSAR) is led by co-founder and chief executive officer Jeffrey L. Cleland. Aisling Capital, managed by Dennis Purcell, held a major stake in Versartis Inc (NASDAQ:VSAR) before the IPO, according to another filing.

Boston-based RA Capital invests in companies with promising drugs and technologies. In the beginning of this month, Ra Capital disclosed a new passive stake in Enanta Pharmaceuticals Inc (NASDAQ:ENTA), owning 1.54 million shares. Last month, RA Capital revealed initiating a new position in SANUWAVE Health Inc. (OTCBB:SNWV) and raising its stake in pSivida Corp. (NASDAQ:PSDV). In the first company, the fund has reported a 9.9% passive stake, which contains around 4.67 million shares. Also, the fund disclosed a new stake in Repros Therapeutics Inc (NASDAQ:RPRX), holding 1.44 million shares.

Disclosure: none

Recommended Reading:

Anchorage Advisors Sells Over 1 Million Shares In Central Pacific Financial Corp. (CPF)

Jeffrey Smith, Starboard Value are Bullish on Unwired Planet Inc (UPIP)

New Changes in SAC Capital’s 13F Portfolio: Annies Inc (BNNY), Cytokinetics, Inc. (CYTK) And Other

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!